Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12752403 | 0.93 | KMT2A (0.41) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1484494 | 0.91 | KDM4E (0.37) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL12828505 | 0.91 | KDM4E (0.33) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL1484469 | 0.91 | KDM4E (0.41) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL12752335 | 0.90 | KMT2A (0.35) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL12752441 | 0.89 | KMT2A (0.35) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL12752333 | 0.89 | KMT2A (0.35) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL12752174 | 0.89 | KMT2A (0.40) | KDM4EALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL12752358 | 0.89 | MEN1 (0.32) | KDM4EALDH1A1HPGDKMT2AMEN1 | |
| SCHEMBL12752407 | 0.89 | MEN1 (0.34) | KDM4EALDH1A1HPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | claimed |
| CN-118063395-A | Preparation method of anti-AIDS drug Ai Nuowei Lin Zhongjian | 成都艾迪医药技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117466825-A | Preparation method of Ai Nuowei Lin Zhongjian body | 南京艾迪医药科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117417302-A | Preparation method of Ai Nuowei forest | 江苏艾迪药业股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117304118-A | Synthesis method of anti-AIDS drug Ai Nuowei forest | 江苏艾迪药业股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117074594-A | Quality control method of Ai Nuowei forest related substances | 扬州艾迪医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-111999396-B | Method for detecting content of anti-mugwort medicine by ultrasonic-assisted ionic liquid dispersion liquid microextraction High Performance Liquid Chromatography (HPLC) | 扬州工业职业技术学院 | 2023-03-14 | — | — | CN | disclosed |
| CN-111999396-A | Method for detecting content of anti-mugwort medicine by ultrasonic-assisted ionic liquid dispersion liquid microextraction High Performance Liquid Chromatography (HPLC) | 扬州工业职业技术学院 | 2020-11-27 | — | — | CN | disclosed |
| CN-106860414-B | anti-HIV compound preparation and preparation method and application thereof | 江苏艾迪药业股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| CN-106860414-A | A kind of compound preparation for AntiHIV1 RT activity and preparation method and application | 江苏艾迪药业有限公司 | 2017-06-20 | — | — | CN | disclosed |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KP) | 2009-03-19 | — | — | US | disclosed |
| WO-2009005693-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005693-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005674-A2 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075939-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | KDM4E 790/4885ALDH1A1 1800/4885HPGD 2033/4885 |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2E, POLR2H | KDM4E 2383/4885ALDH1A1 1058/4885HPGD 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.